» Articles » PMID: 33264472

Acceptability and Potential Impact on Uptake of Using Different Risk Stratification Approaches to Determine Eligibility for Screening: A Population-based Survey

Overview
Journal Health Expect
Publisher Wiley
Specialty Public Health
Date 2020 Dec 2
PMID 33264472
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Using risk stratification approaches to determine eligibility has the potential to improve efficiency of screening.

Objectives: To compare the public acceptability and potential impact on uptake of using different approaches to determine eligibility for screening.

Design: An online population-based survey of 668 adults in the UK aged 45-79 including a series of scenarios in the context of a potential kidney cancer screening programme in which eligibility was determined by age, sex, age and sex combined, a simple risk score (age, sex, body mass index, smoking status), a complex risk score additionally incorporating family history and lifestyle, or a genetic risk score.

Outcome Measures: We used multi-level ordinal logistic regression to compare acceptability and potential uptake within individuals and multivariable ordinal logistic regression differences between individuals.

Results: Using sex, age and sex, or the simple risk score were less acceptable than age (P < .0001). All approaches were less acceptable to women than men. Over 70% were comfortable waiting until they were older if the complex risk score or genetics indicated a low risk. If told they were high risk, 85% would be more likely to take up screening. Being told they were low risk had no overall influence on uptake.

Conclusions: Varying the starting age of screening based on estimated risk from models incorporating phenotypic or genetic risk factors would be acceptable to most individuals and may increase uptake.

Patient Or Public Contribution: Two members of the public contributed to the development of the survey and have commented on this paper.

Citing Articles

Societal views on using risk-based innovations to inform cancer screening and referral policies: findings from three community juries.

Dennison R, Clune R, Tung J, John S, Moorthie S, Waller J BMC Public Health. 2025; 25(1):801.

PMID: 40016715 PMC: 11869612. DOI: 10.1186/s12889-025-21996-x.


Implementation considerations for risk-tailored cancer screening in the population: A scoping review.

Dunlop K, Singh N, Robbins H, Zahed H, Johansson M, Rankin N Prev Med. 2024; 181:107897.

PMID: 38378124 PMC: 11106520. DOI: 10.1016/j.ypmed.2024.107897.


Personalised colorectal cancer screening strategies: Information needs of the target population.

Toes-Zoutendijk E, de Jonge L, Breekveldt E, Korfage I, Usher-Smith J, Lansdorp-Vogelaar I Prev Med Rep. 2023; 35:102325.

PMID: 37601828 PMC: 10433032. DOI: 10.1016/j.pmedr.2023.102325.


Acceptability of risk stratification within population-based cancer screening from the perspective of the general public: A mixed-methods systematic review.

Taylor L, Hutchinson A, Law K, Shah V, Usher-Smith J, Dennison R Health Expect. 2023; 26(3):989-1008.

PMID: 36852880 PMC: 10154794. DOI: 10.1111/hex.13739.


Acceptability of risk stratification within population-based cancer screening from the perspective of healthcare professionals: A mixed methods systematic review and recommendations to support implementation.

Taylor L, Law K, Hutchinson A, Dennison R, Usher-Smith J PLoS One. 2023; 18(2):e0279201.

PMID: 36827432 PMC: 9956883. DOI: 10.1371/journal.pone.0279201.


References
1.
Ogilvie G, Smith L, van Niekerk D, Khurshed F, Pedersen H, Taylor D . Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval. BMC Public Health. 2016; 16:213. PMC: 4776398. DOI: 10.1186/s12889-016-2865-8. View

2.
French D, Cameron E, Benton J, Deaton C, Harvie M . Can Communicating Personalised Disease Risk Promote Healthy Behaviour Change? A Systematic Review of Systematic Reviews. Ann Behav Med. 2017; 51(5):718-729. PMC: 5602036. DOI: 10.1007/s12160-017-9895-z. View

3.
Pashayan N, Morris S, Gilbert F, Pharoah P . Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol. 2018; 4(11):1504-1510. PMC: 6230256. DOI: 10.1001/jamaoncol.2018.1901. View

4.
Dent T, Jbilou J, Rafi I, Segnan N, Tornberg S, Chowdhury S . Stratified cancer screening: the practicalities of implementation. Public Health Genomics. 2013; 16(3):94-9. DOI: 10.1159/000345941. View

5.
Wong M, Goggins W, Yip B, Fung F, Leung C, Fang Y . Incidence and mortality of kidney cancer: temporal patterns and global trends in 39 countries. Sci Rep. 2017; 7(1):15698. PMC: 5691143. DOI: 10.1038/s41598-017-15922-4. View